Kooperativer Bibliotheksverbund

UID:

Format: xxix, 490 Seiten : , Illustrationen, Karten ; , 19 cm.

Edition: Third edition

ISBN: 978-1-9751-7924-3

Series Statement: Oncology

Note: Includes bibliographical references and index

Language: English

Keywords: Handbook

UID:

Format: 1 online resource (319 pages)

Edition: Second edition.

ISBN: 9781496389145 (e-book)

Note: Includes index.

Additional Edition: Print version: Karp, Daniel D. Handbook of targeted cancer therapy and immunotherapy. Philadelphia : Wolters Kluwer, c2019 ISBN 9781496389138

Language: English

Keywords: Electronic books.

URL: Click to View

UID:

Format: 1 online resource (287 pages) : , color illustrations

ISBN: 9781496324481 (e-book)

Additional Edition: Print version: Handbook of targeted cancer therapy. Philadelphia : Wolters Kluwer, [2015] ISBN 9781451193268

Language: English

Keywords: Electronic books.

URL: Click to View

UID:

Format: 1 online resource

Edition: Third edition.

ISBN: 1-9751-7926-9 , 1-9751-7925-0

Note: Includes index. , Intro -- Title Page -- Copyright Page -- Contributors -- Preface -- Acknowledgments -- Contents -- SECTION 1 Targets by Organ Site -- Color Key -- Abbreviations -- Adrenocortical Carcinoma (ACC)-Mouhammed A. Habra, Aung Naing -- Agnostic to Tumor Site-Gerald S. Falchook -- Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct, Cholangiocarcinoma)-Goldy C. George, David S. Hong, Milind Javle, Kathrina Marcelo-Lewis, Ahmed O. Kaseb -- Bladder Carcinoma (Urothelial Cancer)-Arlene O. Siefker-Radtke -- Brain Tumors-Michael Pearlman, Vivek Subbiah Glioblastoma/Malignant Gliomas -- Other NF-Related Tumors -- Medulloblastoma -- Meningiomas -- Breast Cancer-Senthil Damodaran, Debu Tripathy ER/PR+ -- HER2+ -- Triple-Negative/Basal -- Cervical Cancer-Siqing Fu, Laura L. Holman, Shannon N. Westin -- Colorectal Cancer-David S. Hong, E. Scott Kopetz, Allan A. L. Pereira -- Esophageal Cancer (Squamous Cell)-Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy -- Gastric/Gastroesophageal Junction Adenocarcinoma-Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy -- Head and Neck Cancer-Renata Ferrarotto, Sangeeta Goswami, Kathrina Marcelo-Lewis, Sarina A. Piha-Paul, Erminia Massarelli Salivary Gland -- Squamous Cell -- Nasopharynx -- Kidney (Renal Cell) Cancer-Vivek Subbiah, Nizar M. Tannir -- Leukemia-Prajwal C. Boddu, Tapan M. Kadia, Radhika Kainthla, Naveen Pemmaraju Acute Myeloid Leukemia (AML) -- Acute Lymphoblastic Leukemia (ALL) -- Chronic Myeloid Leukemia (CML) -- Chronic Lymphocytic Leukemia (CLL) -- Myeloproliferative Neoplasm (MPN) -- Liver Cancer (Hepatocellular)-Ahmed O. Kaseb, Xiaochun Liu, Shiraj Sen -- Lung Cancer-Niamh Coleman, Daniel D. Karp, Kathrina Marcelo-Lewis, Ralph G. Zinner NSCLC -- SCLC -- Lymphoma-Maliha Khan, Xiaochun Liu, Raphael Steiner, Jason R. Westin. , Multiple Myeloma-Manojkumar Bupathi, Gregory Kaufman, Robert Orlowski -- Ovarian Cancer-Siqing Fu, Laura L. Holman, Shannon N. Westin -- Pancreatic Cancer (Ductal Carcinoma)-Goldy C. George, Milind Javle, Kathrina Marcelo-Lewis, Shubham Pant -- Prostate Cancer (Adenocarcinoma)-Patrick Pilie -- Sarcoma-Anthony Conley, David S. Hong, Jason Roszik, Vivek Subbiah Gastrointestinal Stromal Tumors, GIST -- Sarcoma -- Skin Cancer-Gerald S. Falchook, Meredith A. McKean, Michael K. K. Wong, Scott E. Woodman Melanoma -- Basal Cell -- Squamous Cell -- Merkel Cell -- Small Bowel Cancer-Gerald S. Falchook -- Testicular Cancer (Germ Cell Carcinoma)-Lance C. Pagliaro, Vivek Subbiah -- Thymus Carcinoma (Thymic and Thymoma)-Gerald S. Falchook, Ralph G. Zinner -- Thyroid Cancer-Manojkumar Bupathi, Maria E. Cabanillas, Gerald S. Falchook Papillary and Follicular Carcinoma -- Papillary, Follicular, and Hurthle Cell Carcinoma -- Medullary Carcinoma -- Anaplastic Carcinoma -- Uterine (Endometrial) Cancer-Siqing Fu, Laura L. Holman, Shannon N. Westin -- SECTION 2 Carcinogenesis from the Perspective of Targeted Therapy and Immunotherapy -- SECTION 3 Molecular Targets and Pathways -- An Introduction to the Organization of Cancer Cell Signaling -- Signal Transduction Roadmap -- VEGF and VEGFR -- FGF and FGFR -- PDGF and PDGFR -- Angiopoietin and TIE Receptors -- IGFR and Insulin Receptors -- Targeting IGFR and Insulin Receptors -- TGFβ/SMAD -- EGFR -- EGFR Signaling -- HER2 (Also Known as ERBB2) -- MET (Also Known as HGF Receptor) -- RET Receptor -- ALK Receptor -- KIT Receptor -- ROS Receptor -- Receptor Tyrosine Kinases (Activation Cascade) -- Cell Signaling Pathways Rapamycin and Its Mammalian Target (mTOR) -- PI3K-AKT-mTOR Pathway -- PI3K, AKT, PTEN, TSC in Cancer -- mTORC1,2 -- NF-Kappa B-Master Immune Regulator -- NF-κB Pathway -- G-Protein-Coupled Receptors. , Mitogen-Activated Protein Kinase (MAPK) -- RAS/MAPK Pathway -- Targeting BRAF/MEK -- Rous Sarcoma Virus Oncogene (SRC) -- SRC Pathway -- β-Catenin-Cell Adhesion -- Wnt Pathway -- Fruit Fly Mutations and Related Genes -- Hedgehog Pathway -- NOTCH Pathway -- B-Cell Lymphoma 2 (BCL-2)/Cysteine Aspartates (CASPASES) -- Janus Kinase and Signal Transducer and Transcription -- JAK/STAT Pathway -- Apoptosis (Greek-"Leaves Falling from a Tree") -- Death Receptors (DRs) and Apoptosis -- Nuclear Factors and DNA Repair -- TP53: Master Cell Cycle Regulator -- Cell Regulation by RB1, CDKs -- DNA Damage Response -- Aurora Kinase -- Overview of Angiogenic Signaling -- Angiogenesis: A Hallmark of Cancer -- Angiogenesis Regulators -- Immunotherapy -- Management of Immune-Related Adverse Events (irAEs) -- Epigenetics -- Targeting Epigenetics -- Antibody Drug Conjugates (ADCs) Have Variable "Payloads" and Multiple Microenvironmental Targets -- Tropomyosin-Related Kinases -- Metabolism: Glycolysis and the TCA Cycle -- Targeting Cancer Metabolism -- Ewing Sarcoma Gene Fusion -- SECTION 4 Targeted and Immunotherapy Agents -- Color Key -- Abbreviations -- Abemaciclib -- Abiraterone Acetate -- Acalabrutinib -- Acalisib -- Adavosertib -- Ado-Trastuzumab Emtansine -- Afatinib Dimaleate -- Afuresertib -- Alectinib -- Alemtuzumab (Campath-1H) -- Alisertib -- All-Trans Retinoic Acid (ATRA) -- Alpelisib -- Alrizomadlin -- Altiratinib -- AMG337 -- Amivantamab-vmjw -- Anastrozole -- Andecaliximab (GS-5745) -- Anetumab Ravtansine -- Anlotinib -- Apalutamide -- Apatinib -- Atezolizumab -- Avapritinib -- Avelumab -- Axicabtagene Ciloleucel -- Axitinib -- Belagenpumatucel-L -- Belantamab Mafodotin -- Belinostat -- Belizatinib -- Bemarituzumab -- Bempegaldesleukin -- Berzosertib -- Bevacizumab -- BI 811283 -- Bicalutamide -- Binimetinib -- Bintrafusp Alfa -- Blinatumomab -- BMS-936559. , Bortezomib -- Bosutinib -- Brentuximab Vedotin -- Brexucabtagene Autoleucel -- Brigatinib -- Brivanib Alaninate -- Bryostatin 1 -- Buparlisib -- Cabozantinib -- Camrelizumab -- Capivasertib -- Capmatinib -- Carfilzomib -- Cediranib Maleate -- Cemiplimab -- Ceritinib -- Cetuximab -- Cevostamab -- Ciltacabtagene Autoleucel -- Cixutumumab -- Cobimetinib Fumarate -- Copanlisib -- Crenolanib Besylate -- Crizotinib -- Dabrafenib -- Dacomitinib -- Dactolisib -- Danvatirsen -- Daratumumab -- Darolutamide -- Darovasertib -- Dasatinib -- Debio-1347 -- Demcizumab -- Dostarlimab -- Double Antiangiogenic Protein -- Dovitinib -- Durvalumab -- Duvelisib -- Elotuzumab -- Enasidenib Mesylate -- Encorafenib -- Enfortumab Vedotin -- Ensartinib -- Entrectinib -- Enzalutamide -- Enzastaurin -- Epratuzumab -- Erdafitinib -- Erlotinib -- Everolimus -- Farletuzumab -- Ficlatuzumab -- Figitumumab -- Foretinib -- Fostamatinib Disodium -- Fulvestrant -- Futibatinib -- Galunisertib -- Ganitumab -- Gefitinib -- Geldanamycin -- Gemtuzumab Ozogamicin -- Gilteritinib Fumarate -- Glasdegib Maleate -- Ibrutinib -- Icotinib -- Idecabtagene Vicleucel -- Idelalisib -- Imatinib Mesylate -- Imifoplatin397 -- Iniparib -- Inotuzumab Ozogamicin -- Ipafricept -- Ipatasertib -- Ipilimumab -- Isatuximab -- Ivosidenib -- Lanreotide -- Lapatinib Ditosylate -- Larotrectinib -- Lenalidomide -- Lenvatinib Mesylate -- LGK974 -- Linifanib -- Linsitinib -- Loncastuximab Tesirine -- Lorlatinib -- Lucitanib -- Lurbinectedin -- Lutetium Lu 177 Dotatate -- Margetuximab-cmkb -- Matuzumab -- Midostaurin -- Milademetan -- Miransertib -- Mirvetuximab Soravtansine -- MK-0752 -- MK-2206 -- MK-8242 -- MKC-1 -- Mocetinostat -- Mogamulizumab-kpkc -- Momelotinib -- nab-Rapamycin -- Napabucasin -- Naquotinib Mesylate -- Navitoclax -- Nazartinib -- Necitumumab -- Neratinib -- Nilotinib -- Nintedanib -- Niraparib. , Nirogacestat -- Nivolumab -- Obatoclax Mesylate -- Obinutuzumab -- Ofatumumab -- Olaparib -- Olaratumab -- Olmutinib -- Onartuzumab -- Onatasertib -- Osimertinib -- Pacritinib -- Palbociclib -- Panitumumab -- Panobinostat -- Parsaclisib -- Pazopanib Hydrochloride -- Pelareorep -- Pembrolizumab -- Pemetrexed -- Pemigatinib -- Peposertib -- Perifosine -- Pertuzumab -- Pexidartinib -- Pilaralisib -- Pimasertib -- Pomalidomide -- Ponatinib Hydrochloride -- Poziotinib -- Pralatrexate -- Pralsetinib -- Prexasertib -- Pyrotinib -- Quizartinib -- Ramucirumab -- Razuprotafib -- RC48-ADC -- Rebastinib -- Refametinib -- Regorafenib -- Ridaforolimus -- Rigosertib -- Rilotumumab -- Ripretinib -- Rituximab -- Romidepsin -- Rovalpituzumab Tesirine -- Rucaparib Camsylate -- Ruxolitinib Phosphate -- Sacituzumab Govitecan -- Sapanisertib -- Saracatinib -- Selinexor -- Selitrectinib -- Selpercatinib -- Selumetinib -- Serabelisib -- Sintilimab -- Sipuleucel-T -- Sirolimus -- Sitravatinib -- Sonidegib -- Sonolisib -- Sorafenib -- Sotatercept -- Sotorasib -- Spartalizumab -- Sunitinib -- TAK580 -- Taladegib -- Talazoparib Tosylate -- Taletrectinib -- Talimogene Laherparepvec -- Talquetamab -- Tazemetostat Hydrobromide -- Teclistamab -- Telaglenastat -- Telatinib -- Temsirolimus -- Tepotinib -- Thalidomide -- Tipifarnib -- Tirabrutinib -- Tisagenlecleucel -- Tisotumab Vedotin-tftv -- Tivantinib -- Toripalimab -- Trabectedin -- Trabedersen -- Trametinib -- Trastuzumab -- Trebananib -- Tremelimumab -- Tucatinib -- Ulixertinib -- Uprosertib -- Urelumab -- Vadastuximab Talirine -- Valproic Acid -- Vandetanib -- Vanucizumab -- Vatalanib -- Veliparib -- Vemurafenib -- Venetoclax -- Vevorisertib -- Vismodegib -- Vistusertib -- Vocimagene Amiretrorepvec -- Vopratelimab -- Vorinostat -- Xentuzumab -- Zalutumumab -- Zanidatamab -- Zanubrutinib -- Ziv-Aflibercept -- Zotatifin. , Index.

Additional Edition: ISBN 1-9751-7924-2

Language: English

UID:

Format: 1 online resource (xix, 267 pages) : , color illustrations.

Edition: 1st ed.

ISBN: 1-4698-9458-0 , 1-4963-2448-X

Content: Make optimal use of the latest personalized therapeutic strategies with Handbook of Targeted Cancer Therapy! This concise, practical oncology reference examines more than 120 targeted therapy agents for which clinical trial data are available, and explains when and how you can use them to most effectively combat cancer. Approach clinical challenges from any direction with separate sections on Targets by Organ Site, Carcinogenesis from the Perspective of Targeted Therapy, Molecular Targets and Pathways, and Targeted Therapy Agents; find information easily thanks to a color-coded format and an intuitive organization; access the complete contents online and on mobile devices, with regular updates to include newly approved treatments and important state of the art cancer information for caregivers, researchers, other health care professionals, and even patients.Now with the print edition, enjoy the bundled interactive eBook edition, offering tablet, smartphone, or online access to: complete content with enhanced navigation; a powerful search tool that pulls results from content in the book, your notes, and even the web; cross-linked pages, references, and more for easy navigation; highlighting tool for easier reference of key content throughout the text; ability to take and share notes with friends and colleagues and quick-reference tabbing to save your favorite content for future use.

Note: Section 1. Targets by organ site -- Section 2. Carcinogenesis from the perspective of targeted therapy -- Section 3. Molecular targets and pathways -- Section 4. Targeted therapy agents. , English

Additional Edition: ISBN 1-4511-9326-2

Language: English

UID:

Format: 1 online resource (319 pages)

Edition: 2nd ed.

ISBN: 1-4963-8914-X

Content: "The exponential growth of oncology drug development and personalized/targeted therapy in the recent years has presented a challenge to even the most experienced cancer researchers. Many of us struggle to keep up with the hundreds of clinical trials conducted each year. To help with this challenge, we present here the second edition of our concise handbook intended to make the results of clinical trials of targeted cancer treatments and immunotherapy more easily accessible to cancer researchers and clinicians. We are very proud of the reception the first edition received from oncologists, medical staff, students, and even patients, and we are excited about the updated and widely expanded content included in this second edition"--Provided by publisher.

Note: Includes index. , Intro -- Title Page -- Copyright Page -- Contributors -- Preface -- Acknowledgements -- Contents -- Section 1 Targets by Organ Site -- Abbreviations -- Adrenocortical Carcinoma (ACC) -- Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct) -- Bladder Carcinoma (Urothelial Cancer) -- Brain Tumors -- Glioblastoma/Malignant Gliomas -- Other NF-Related Tumors -- Medulloblastoma -- Meningiomas -- Breast Cancer -- ER/PR+ -- HER2+ -- Triple-Negative/Basal -- Cervical Cancer -- Colorectal Cancer -- Esophageal Cancer (Squamous Cell) -- Gastric/Gastroesophageal Junction (Adenocarcinoma) -- Head and Neck Cancer -- Salivary Gland -- Squamous Cell -- Nasopharynx -- Kidney (Renal Cell) Cancer -- Leukemia -- Acute Myeloid Leukemia (AML) -- Acute Lymphoblastic Leukemia (ALL) -- Chronic Myeloid Leukemia (CML) -- Chronic Lymphocytic Leukemia (CLL) -- Myeloproliferative Neoplasm (MPN) -- Liver Cancer (Hepatocellular) -- Lung Cancer -- NSCLC -- SCLC -- Lymphoma -- Multiple Myeloma -- Ovarian Cancer -- Pancreatic Cancer (Ductal Carcinoma) -- Prostate Cancer (Adenocarcinoma) -- Sarcoma (Gastrointestinal Stromal Tumors, GIST) -- Sarcoma -- Skin Cancer -- Melanoma -- Basal Cell -- Squamous Cell -- Merkel Cell -- Testicular Cancer (Germ Cell Carcinoma) -- Thymus Carcinoma (Thymic and Thymoma) -- Thyroid Cancer -- Papillary and Follicular Carcinoma -- Papillary, Follicular, and Hurthle Cell Carcinoma -- Medullary Carcinoma -- Anaplastic Carcinoma -- Uterine (Endometrial) Cancer -- Section 2 Carcinogenesis from the Perspective of Targeted Therapy and Immunotherapy -- Section 3 Molecular Targets and Pathways -- Signal Transduction-The Big Picture -- Color Key -- Angiogenesis -- Angiogenesis Regulators -- Targeting HIF-1α -- Receptor Tyrosine Kinases -- VEGFR Signaling and Targeting VEGFR -- FGFR Signaling and Targeting FGFR -- Aberrations in FGFR Associated with Cancer. , Targeting the FGFR Pathway -- PDGFR and Targeting PDGFR -- TIE Receptors -- IGFR-1 and Insulin Receptor -- Targeting IGFR-1 and Insulin Receptor -- TGFβ/SMAD Pathway -- Targeting TGFβ/SMAD Pathway -- EGFR Family of Receptors -- EGFR Signaling in Cancer -- EGFR Alterations -- Targeting EGFR -- HER2 -- ERBB2/HER2 Alterations in Cancer -- Targeting HER2 -- HGF Receptors: MET -- Targeting MET -- RET Receptor -- ALK Receptor -- ALK Alterations -- KIT -- Targeting KIT -- ROS-1 Receptor -- Targeting ROS-1 -- G-Protein-Coupled Receptors -- RAS/MAPK Pathway -- MAPK Pathway -- Targeting RAS -- Targeting BRAF -- Targeting MEK -- PI3K Pathway -- PI3K-AKT-mTOR Pathway -- Targeting PI3K Mutations -- Targeting AKT Mutations -- Targeting PTEN and TSC Alterations -- Targeting mTORC1 and mTORC2 -- JAK/STAT Pathway -- Targeting JAK -- Hedgehog Signaling Pathway -- NOTCH Pathway -- Wnt Pathway -- SRC Pathway -- NFκb Pathway -- Death Receptors and Apoptosis -- Cell Cycle Regulation -- TP53 -- RB1 -- CDKN2A -- DNA Damage Response -- Targeting DNA Damage Response -- Aurora Kinases -- Immunotherapy -- Targeting PD-1 and PD-L1 -- Immunotherapy -- Targeting CTLA-4 -- Immunotherapy -- Management of Immune-Related Diarrhea and Colitis -- Management of Immune-Related Hepatitis -- Management of Immune-Related Pneumonitis -- Management of Immune-Related Nephritis -- Management of Immune-Related Skin Rash/Toxicities -- Management of Immune-Related Peripheral Neurologic Toxicities -- Management of Immune-Related Thyroid Function Adverse Events -- Epigenetics -- Targeting Epigenetics in Cancer -- Antibody-Drug Conjugates -- TRK Signaling Pathway -- Targeting Cancer Metabolism -- Ewing Sarcoma Gene Fusion Partners -- Section 4 Targeted and Immunotherapy Agents -- Color Key -- Abbreviations -- Abiraterone Acetate (Zytiga) -- Acalabrutinib (Calquence). , Ado-Trastuzumab Emtansine (Kadcyla) -- Afatinib Dimaleate (Gilotrif) -- Afuresertib -- Alectinib (Alecensa) -- Alemtuzumab (Campath-1h) -- Alisertib -- Alpelisib -- Apatinib -- Atezolizumab (Tecentriq) -- Avelumab (Bavencio) -- Axicabtagene Ciloleucel (Yescarta) -- Axitinib (Inlyta) -- Anetumab Ravtansine -- AZD-1775 -- AZD9150 -- Belinostat (Beleodaq) -- Bevacizumab (Avastin) -- BI 811283 -- Bicalutamide (Casodex/Cosudex) -- Binimetinib -- Blinatumomab (Blincyto) -- BMS-936559 -- Bortezomib (Velcade) -- Bosutinib (Bosulif) -- Brentuximab Vedotin (Adcetris) -- Brigatinib (Alunbrig) -- Brivanib Alaninate -- Buparlisib -- Cabozantinib (Cometriq) -- Carfilzomib (Kyprolis) -- Cediranib -- Ceritinib (Zykadia) -- Cetuximab (Erbitux) -- Cixutumumab -- Cobimetinib (Cotellic) -- Combretastatin Disodium -- Copanlisib (Aliqopa) -- Crizotinib (Xalkori) -- Dabrafenib (Tafinlar) -- Dacomitinib -- Dactolisib -- Daratumumab (Darzalex) -- Dasatinib (Sprycel) -- Denosumab (Xgeva) -- Dovitinib -- Durvalumab (Imfinzi) -- Elotuzumab (Empliciti) -- Enasidenib Mesylate (Idhifa) -- Encorafenib -- Enzalutamide (Xtandi) -- Epratuzumab -- Erlotinib (Tarceva) -- Everolimus (Afinitor) -- Farletuzumab -- Figitumumab -- Foretinib -- Fostamatinib Disodium -- Galunisertib -- Ganitumab -- Gefitinib (Iressa) -- Gemtuzumab Ozogamicin (Mylotarg) -- Idelalisib (Zydelig) -- Ibrutinib (Imbruvica) -- Imatinib Mesylate (Gleevec) -- INC280 -- Iniparib -- Inotuzumab Ozogamicin -- Ipilimumab (Yervoy) -- Ivosidenib -- Lapatinib Ditosylate (Tykerb) -- Lenalidomide (Revlimid) -- Lenvatinib Mesylate (Lenvima) -- LGK974 -- Linifanib -- Linsitinib -- Lonafarnib -- LOR-253 HCL -- Larotrectinib -- LOXO-292 -- LY2157299 -- Mocetinostat -- Mogamulizumab (Poteligeo) -- Masitinib Mesylate -- Matuzumab -- MEDI0639 -- Midostaurin (Rydapt) -- Mirvetuximab Soravtansine -- MK-0752 -- MK-2206 -- MK-8242 -- MKC-1. , MSC2156119J -- Navitoclax -- Necitumumab (Portrazza) -- Neratinib (Nerlynx) -- Nilotinib (Tasigna) -- Nimotuzumab -- Nintedanib -- Niraparib (Zejula) -- Nivolumab (Opdivo) -- Obinutuzumab (Gazyva) -- Ofatumumab (Arzerra) -- Olaparib (Lynparza) -- Omipalisib -- Olaratumab (Lartruvo) -- OMP-54F28 -- Onartuzumab -- Orantinib -- Osimertinib (Tagrisso) -- Pacritinib -- Palbociclib (Ibrance) -- Panitumumab (Vectibix) -- Panobinostat -- Pazopanib Hydrochloride (Votrient) -- PEG-interferon alfa-2b (Sylatron) -- Pembrolizumab (Keytruda) -- Pemetrexed (Alimta) -- Perifosine -- Pertuzumab (Perjeta) -- PF-03814735 -- Pilaralisib -- Pimasertib -- Pomalidomide (Pomalyst) -- Ponatinib Hydrochloride (Iclusig) -- Poziotinib -- Pralatrexate (Folotyn) -- PRI-724 -- Quizartinib -- Ramucirumab (Cyramza) -- Refametinib -- Regorafenib (Stivarga) -- Reolysin -- Ridaforolimus -- Rigosertib -- Rilotumumab -- Rituximab (Rituxan) -- Romidepsin (Istodax) -- Rovalpituzumab Tesirine -- Rucaparib Camsylate (Rubraca) -- Ruxolitinib Phosphate (Jakafi) -- Salirasib -- Saracatinib -- Selinexor -- Selumetinib -- Sipuleucel-T (Provenge) -- Sirolimus (Rapamune) -- Sonidegib (Odomzo) -- Sonolisib -- Sorafenib (Nexavar) -- Sunitinib (Sutent) -- Talimogene Laherparepvec (Imlygic) -- Talazoparib -- Telatinib -- Temsirolimus (Torisel) -- Teprotumumab -- Tipifarnib -- Tisagenlecleucel (Kymriah) -- Tivantinib -- Trabectidin (Yondelis) -- Trabedersen -- Trametinib (Mekinist) -- Trastuzumab (Herceptin) -- Tremelimumab -- Triciribine -- Trebananib -- Trifluridine and Tipiracil (Lonsurf) -- Valproic Acid (Depakote) -- Vandetanib (Caprelsa) -- Vantictumab -- Vanucizumab -- Veliparib -- Vemurafenib (Zelboraf) -- Venetoclax (Venclexta) -- Vismodegib (Erivedge) -- Vocimagene Amiretrorepvec -- Vorinostat (Zolinza) -- Zalutumumab -- Ziv-Aflibercept (Zaltrap) -- Index.

Additional Edition: ISBN 1-4963-8913-1

Language: English

Keywords: Handbooks